




Trojan Fund (Ireland)


All data as at 31 May 2020

www.taml.co.uk

The Fund seeks to achieve growth in capital, ahead of inflation (UK Retail Price Index), over the longer term (5 to 7 years). The Fund employs a long-term, long only approach and has the flexibility to invest across a broad range of asset classes, most commonly a combination of high-quality developed market equities, developed market government bonds, gold related investments and cash.

Prices		Fund Size
1.3964 GBP O acc	1.3751 GBP O inc	£365m
1.4376 USD O acc	1.4119 USD O inc	
1.2860 EUR O acc	1.2663 EUR O inc	
1.4757 SGD O acc	1.4679 SGD O inc	





Total Return to 31 May 2020	13/02/2012 Since launch	31/05/15 5 years	31/05/17 3 years	31/05/19 1 year	30/11/19 6 months
Trojan Fund (Ireland) (O Acc GBP)	+39.6%	+30.7%	+11.3%	+8.9%	+5.3%
UK Official Bank Rate	+4.2%	+2.5%	+1.7%	+0.6%	+0.2%
UK Retail Price Index	+22.9%	+13.2%	+7.7%	+1.2%	+0.5%

Discrete Calendar Annual Returns	2012#	2013	2014	2015	2016	2017	2018	2019	2020 YTD
Trojan Fund (Ireland) (O Acc GBP)	-0.1%	-3.5%	+8.2%	+2.9%	+11.8%	+3.9%	-3.0%	+10.3%	+4.6%

Source: Lipper

Past performance is not a guide to future performance

NB: Prior to its conversion on 29 March 2019 the Fund was a feeder fund called the Trojan Feeder Fund (Ireland).

May Commentary

Your Fund (O Acc GBP) returned +1.5% during the month.

Stock markets have cheered as Western governments began to ease lockdowns and the rate of new coronavirus cases in several countries slowed. We remain sceptical that the path to normalcy is as clear as the rally in share prices would suggest.

For those companies we own, earnings releases in the month have provided us with some insights into how they are faring. We deliberately favour well-capitalised companies with broad end-market exposures, enabling them to endure and

survive bouts of hardship. Two such examples are Medtronic and Agilent, both new to the portfolio over the past year, and performing positively.

Medtronic is the world's largest medical device manufacturer, with products to treat a wide range of illnesses from cardiovascular disease to diabetes. With COVID-19 leading to the deferral of many elective surgical procedures, Medtronic saw its sales decline -25% in the quarter. The majority of these sales are likely to return, as they cannot be deferred indefinitely without major risk to patients' health. Thanks to the strength of its

balance sheet, Medtronic is able to continue investing behind its people and products, including remote-monitoring technology, an increasingly prized capability in the current environment.

Agilent meanwhile saw flat sales growth in the quarter, with demand for its testing equipment growing in health-related sectors, offsetting weakness in academic and energy-related sales. Geographic diversity also aided the resilience with its China business returning to growth. The company's financial strength enables it to continue investing behind its best opportunities.

Return vs volatility since launch (13/02/2012)



Risk analysis since launch (13/02/2012)	Trojan Fund (Ireland) ^{O Acc GBP}
Total Return	+39.6%
Max Drawdown ¹	-10.1%
Best Month	+4.9%
Worst Month	-4.7%
Positive Months	+60.6%
Annualised Volatility ²	+5.5%

Source: Lipper¹ Measures the worst investment period ² Measured by standard deviation of annual returns

Top 10 holdings (excluding government bonds)	% Fund
Gold Bullion Securities	7.6
Microsoft	5.4
Alphabet	4.0
Unilever	3.8
Nestlé	3.5
Diageo	3.1
Visa	3.0
Philip Morris	2.9
British American Tobacco	2.8
Medtronic	2.6
Total Top 10	38.8
17 other holdings	43.7
UK T-Bills	3.2
Cash	14.3
TOTAL	100.0

Source: Factset, holdings subject to change

Fund information

A copy of the latest Prospectus (in English) and the KIIDs for each class (in English and German) upon which you should base your investment decision, is available from Link Fund Administrators (Ireland) Ltd, the Fund's Administrator and Registrar (Authorised and Regulated by the Central Bank of Ireland) on (+353) 1 400 5300.

Structure

Sub-fund of Trojan Funds (Ireland) plc UCITS authorised by the Central Bank of Ireland

Investment Manager

Troy Asset Management Limited 33 Davies Street London W1K 4BP Tel: +44 (0)20 7499 4030

Fax: +44 (0)20 7491 2445 email: busdev@taml.co.uk

Fund Manager	Sebastian Lyon
Assistant Fund Manager	Charlotte Yonge
Currencies	f Sterling, \$ US Dollar*,
Hedged shareclass	€ Euro, \$ SGD*
Fund Launch Date	13 February 2012

Benchmarks

For more information on the benchmarks used please refer to the 'use of benchmarks' section in the fund information sheet, available from our <u>website</u>

Ongoing Charges

'O' (ordinary) shares: 1.13%

Dividend Ex Dates

1 August (interim), 1 February (final)

Dividend Pay Dates

30 September (interim) 31 March (final)

Historic Fund Yield ('O' Inc GBP)

0.05%

Administrator

Link Fund Administrators (Ireland) Limited 2 Grand Canal Square Grand Canal Harbour Dublin 2, Ireland Tel: (+353) 1 400 5300

Minimum Investment

f Sterling, \$ US Dollar, € Euro, \$ SGD 250,000

(An initial charge of 5% applies, which may be waived)

Dealing

Daily at 11am (UK) Tel: (+353) 1 400 5300

Registrar

Link Fund Administrators (Ireland) Limited

Auditor

Ernst & Young LLP

Depositary

The Bank of New York Mellon SA/NV, Dublin branch

Bloomberg

TROITOA_ID (O GBP Acc), TROITOI_ID (O GBP Inc)

ISIN

IE00B6127M75 (GBP O Inc), IE00B757JT68 (GBP O Acc)
IE00B6SBBX64 (USD O Inc), IE00B7483W12 (USD O Acc)
IE00B54VKZ87 (EUR O Inc), IE00B6T42S66 (EUR O Acc)
IE00BGM16B55 (SGD O Inc), IE00BGM16C62 (SGD O Acc)

Fund performance data provided is calculated net of fees unless stated otherwise. Past performance is not a guide to future performance. Overseas investments may be affected by movements in currency exchange rates. The value of an investment and any income from it may fall as well as rise and investors may get back less than they invested. The historic yield reflects distributions declared over the past twelve months as a percentage of the fund's price, as at the date shown. It does not include any preliminary charge and investors may be subject to tax on their distributions. The yield is not guaranteed and will fluctuate. The fund may use currency forward derivatives for the purpose of efficient portfolio management. Neither the views nor the information contained within this document constitute investment advice or an offer to invest or to provide discretionary investment management services and should not be used as the basis of any investment decision. Any decision to invest should be based on information contained in the prospectus, the relevant key investor information document and the latest report and accounts. The investment policy and process of the fund(s) may not be suitable for all investors. If you are in any doubt about whether the fund(s) is/are suitable for you, please contact a professional adviser. References to specific securities are included for the purposes of illustration only and should not be construed as a recommendation to buy or sell these securities.

Although Troy Asset Management Limited considers the information included in this document to be reliable, no warranty is given as to its accuracy or completeness. The opinions expressed are expressed at the date of this document and, whilst the opinions stated are honestly held, they are not guarantees and should not be relied upon and may be subject to change without notice. Third party data is provided without warranty or liability and may belong to a third party.

In line with the Fund's prospectus, the Fund is authorised to invest in transferable securities and money market instruments issued or guaranteed by an EEA state, one or more local authorities, a third country, or a public international body to which one or more EEA states belong. The Investment Manager would only consider investing more than 35% of the Fund's assets in UK or US government issued transferable securities or approved money market instruments.

This document relates to one or more sub-funds of Trojan Funds (Ireland) plc. Trojan Funds (Ireland) plc is authorised in Ireland by the Central Bank of Ireland and is a scheme recognised by the UK Financial Conduct Authority (FCA). With the exception of Austria, Germany, Spain, Switzerland and UK, neither Fund is registered for distribution to the public in any jurisdiction. Neither Fund may be marketed in other jurisdictions except in reliance on relevant exemptions. Each Fund is authorised in the United Kingdom by the FCA.

Investors in Germany, Austria and Spain may obtain a copy of the prospectus, relevant key investor information document(s), memorandum and articles of association and financial statements in English (with the exception of the KIIDs which are also available in German and Spanish) free of charge from www.fundinfo.com and/or the respective information agent. The Funds' information agent In Germany is Zeidler Legal Services, Bettinastraße 48, 60325, Frankfurt, Germany. The Funds' information agent in in Austria is Erste Bank, Graben 21, 1010 Wien, Österreich. This document may be made available only to professional investors in Germany, Austria or Spain and should not be passed to anyone in these countries other than a professional investor.

Investors in Switzerland can obtain a copy of the prospectus, the key investor information document(s) (edition for Switzerland), the memorandum and articles of association, the latest annual and semi-annual report, and further information free of charge from the representative in Switzerland: Carnegie Fund Services S.A., 11, rue du Général-Dufour, CH-1204 Geneva, Switzerland, web: www.carnegie-fund-services.ch. The Swiss paying agent is: Banque Cantonale de Genève, 17, quai de l'Ile, CH-1204 Geneva, Switzerland. The latest share prices can be found on www.fundinfo.com. In respect of Shares distributed in Switzerland the place of jurisdiction is at the registered office of the representative in Switzerland.

The offering of Shares has not been and will not be notified to the Belgian Financial Services and Markets Authority (Autoriteit voor Financiële Diensten en Markten/Autorité des Services et Marchés Financiers). The Shares may be offered in Belgium only to a maximum of 149 investors or to investors investing a minimum of €250,000 or to professional or institutional investors, in reliance on Article 5 of the Belgian Law of 3 August 2012. This document may be distributed in Belgium only to such investors for their personal use and exclusively for the purposes of information. Accordingly, this document may neither be used for any other purpose nor passed on to any other person in Belgium.

The Fund is registered for distribution in Italy for professional investors only.

In Singapore, the offer or invitation to subscribe for or purchase Shares is an exempt offer made only: (i) to "institutional investors" pursuant to Section 304 of the Securities and Futures Act, Chapter 289 of Singapore (the "Act"), (ii) to "relevant persons" pursuant to Section 305(1) of the Act, (iii) to persons who meet the requirements of an offer made pursuant to Section 305(2) of the Act, or (iv) pursuant to, and in accordance with the conditions of, other applicable exemption provisions of the Act. This document may not be provided to any other person in Singapore.

Issued by Troy Asset Management Limited, 33 Davies Street, London W1K 4BP (registered in England & Wales No. 3930846). Registered office: Hill House, 1 Little New Street, London EC4A 3TR. Authorised and regulated by the Financial Conduct Authority (FRN: 195764).

Copyright Troy Asset Management 2020